February 27, 2025
Oncopeptides publishes year-end report 2024
Media
February 26, 2025
Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02
February 25, 2025
Oncopeptides – Strong real-world efficacy and safety data with Pepaxti published in the European Journal of Haematology
February 25, 2025
BONESUPPORT HOLDING AB (publ) – publishes year end report 2024
February 20, 2025
Oncopeptides – Invitation to presentation of the year-end report 2024
February 19, 2025
Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results
February 18, 2025
BONESUPPORT HOLDING AB (publ) – Invitation to Conference Call and Webcast for Year-End Report 2024
February 12, 2025
Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer
February 07, 2025
Hemab Therapeutics Presents Interim Data from Ongoing Phase 2 Study of HMB-001 as First Ever Prophylactic Treatment in Glanzmann Thrombasthenia and Preclinical Data from HMB-002 in Von Willebrand Disease at the 2025 EAHAD Annual Congress
February 06, 2025
U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy